The second CXCR2 antagonist, AZD4721 (also known as RIST4721), is evaluated in phase II studies for two types of chronic inflammatory skin diseases and for Familial Mediterranean fever (FMF). Here, CXCR2 is linked to familial Mediterranean fever.